EASL Studio Podcast: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and prevention

EASL Studio Podcast: SLD nomenclature: Need for refinement?

EASL Studio Podcast: Exploring new frontiers: The AI liver taskforce initiative

EASL Studio Podcast: Breaking boundaries: Innovating the future of hepatitis B and D treatment together

EASL Studio Podcast: New therapeutic options and remaining challenges in PBC

EASL Studio Podcast: Education at the heart of EASL’s mission

EASL Studio Podcast: MASLD anno 2024: A rapidly changing landscape

EASL Studio Podcast: Advances in systemic treatments in liver cancer

EASL Studio Podcast: Buongiorno Milano: What not to miss during EASL Congress

EASL Studio Podcast S6 E15: What‘s hot in viral hepatitis in 2024?

EASL Studio S6 E15: What‘s hot in viral hepatitis in 2024?

EASL Studio Podcast S6 E14: Endohepatology: The endoscopic liver gold rush

EASL Studio S6 E14: Endohepatology: The endoscopic liver gold rush

EASL Studio Podcast S6 E13: Resmetirom: First approved drug for MASH, for whom and for how long?

EASL Studio S6 E13: Resmetirom: First approved drug for MASH, for whom and for how long?

EASL Studio S6 E12: Do we care enough about the importance of DILI/DHILI ?

EASL Studio Podcast S6 E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?

EASL Studio S6 E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?

EASL Studio Podcast S6 E10: YI Choice: Citizen science: Societal engagement in hepatology

EASL Studio S6 E10: YI Choice: Citizen science: Societal engagement in hepatology